Skip to content

Study · Non-randomized trial · n = 12 · 2013

2 results

[The tetrapeptide pankragen forte efficiency in elderly people with prediabetic state].

Korkushko OV, Chizhovа VP, Shatilo VB, Khavinson VK

Advances in gerontology = Uspekhi gerontologii1 Jan 2013

PMID28976155 (opens in a new tab)PepBankPUB-28976155
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In 50 percent of older patients with impaired glucose tolerance, pankragen forte significantly decreased plasma glucose during oral glucose tolerance testing.

    In plain wordsIn 50 percent of older patients with impaired glucose tolerance, pankragen forte significantly reduced plasma glucose during glucose testing.

    Peptide
    Pancragen (KEDW)
    Outcome
    DecreasePlasma glucose during oral glucose tolerance testing
    Study

    n = 12

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    500 mkg 2 times a day (morning and evening) · 4 weeksAs given in this study (human).

    Measurements

    Proportion with significant glucose decrease
    50 percent
    older people with impaired glucose tolerance

    Source sentences

    Summary
    In 50 percent older people with impaired glucose tolerance use of pankragen forte led to a significant decrease in the concentration of plasma glucose during a standard oral glucose tolerance test,
    1 context sentence
    Summary · context
    As a result of screening, 69 seniors were selected 12 patients with impaired glucose tolerance, which, for the correction of glucose metabolism used Pankragen-forte as follows: 500 mkg 2 times a day (morning and evening) for 4 weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In older patients with impaired glucose tolerance, pankragen forte use was consistent with improved serum lipid composition and endothelial function and decreased platelet aggregation.

    In plain wordsIn older patients with impaired glucose tolerance, pankragen forte treatment was consistent with better blood lipids, blood vessel function and less platelet clumping.

    Peptide
    Pancragen (KEDW)
    Outcome
    Direction not reportedSerum lipid composition, endothelial function and platelet aggregation
    Study

    n = 12

    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    500 mkg 2 times a day (morning and evening) · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    which is consistent with the improvement of the lipid composition of serum blood, endothelial function, decreased platelet aggregation.
    1 context sentence
    Summary · context
    As a result of screening, 69 seniors were selected 12 patients with impaired glucose tolerance, which, for the correction of glucose metabolism used Pankragen-forte as follows: 500 mkg 2 times a day (morning and evening) for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.